Xtant Medical (XTNT) Expected to Announce Earnings on Tuesday

Key Points

• Upcoming Q1 2026 earnings: Xtant Medical is expected to report Q1 2026 results after the close on Tuesday, May 12, with analysts forecasting an EPS loss of ($0.015) and revenue of $20.164 million; an earnings call is set for May 15 at 4:00 PM ET.
• Recent results show variability: In the prior quarter (reported March 31) Xtant posted EPS of $0.03 and revenue of $32.36 million—above estimates—highlighting a swing versus the lower revenue projected for Q1 2026.
• Market position and sentiment: The company has a market cap of $82.18 million, a P/E of 19.56, roughly 69% institutional ownership, and an average analyst rating of "Buy" with a $1.00 price target.

Xtant Medical (NYSEAMERICAN:XTNT - Get Free Report) is expected to be issuing its Q1 2026 results after the market closes on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.0150) per share and revenue of $20.1640 million for the quarter. Parties are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Friday, May 15, 2026 at 4:00 PM ET.

Xtant Medical (NYSEAMERICAN:XTNT - Get Free Report) last issued its quarterly earnings results on Tuesday, March 31st. The medical device company reported $0.03 earnings per share (EPS) for the quarter. The business had revenue of $32.36 million for the quarter, compared to the consensus estimate of $30.75 million. Xtant Medical had a return on equity of 10.27% and a net margin of 3.71%.

Xtant Medical Price Performance

NYSEAMERICAN:XTNT traded up $0.03 during trading hours on Tuesday, reaching $0.59. 77,672 shares of the company were exchanged, compared to its average volume of 157,284. The company has a market capitalization of $82.18 million, a P/E ratio of 19.56 and a beta of -0.11. Xtant Medical has a 1-year low of $0.44 and a 1-year high of $0.95. The company has a debt-to-equity ratio of 0.22, a current ratio of 2.65 and a quick ratio of 1.63. The business has a 50 day moving average of $0.55 and a 200 day moving average of $0.64.

Institutional Investors Weigh In On Xtant Medical

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Jane Street Group LLC bought a new stake in Xtant Medical during the second quarter worth $26,000. Wiregrass Investment Management LLC bought a new stake in Xtant Medical during the fourth quarter worth $81,000. Mink Brook Asset Management LLC lifted its stake in Xtant Medical by 125.8% during the second quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company's stock worth $81,000 after purchasing an additional 60,997 shares during the last quarter. Renaissance Technologies LLC lifted its stake in Xtant Medical by 28.8% during the fourth quarter. Renaissance Technologies LLC now owns 919,860 shares of the medical device company's stock worth $721,000 after purchasing an additional 205,945 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in Xtant Medical by 4.6% during the third quarter. Vanguard Group Inc. now owns 2,355,671 shares of the medical device company's stock worth $1,529,000 after purchasing an additional 104,159 shares during the last quarter. 69.33% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

XTNT has been the topic of a number of analyst reports. Craig Hallum reissued a "buy" rating on shares of Xtant Medical in a research report on Wednesday, March 18th. BTIG Research reduced their price target on Xtant Medical from $1.50 to $1.00 and set a "buy" rating on the stock in a research report on Tuesday, March 31st. Two research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $1.00.

Xtant Medical Company Profile

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company's product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company's offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.